Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma

The activity of systemic agents after progression when using vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibition (TKI) and mammalian target of rapamycin (mTOR) inhibition in patients with metastatic renal cell carcinoma (mRCC) is poorly characterized.02/05/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news